4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > CRISPR_Cell_lines > CellGenix/CellGenix®rh IL-6/1 mg/1004-1000
商品详细CellGenix/CellGenix®rh IL-6/1 mg/1004-1000
CellGenix/CellGenix®rh IL-6/1 mg/1004-1000
CellGenix/CellGenix®rh IL-6/1 mg/1004-1000
商品编号: 1004-1000
品牌: CellGenix
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: CRISPR 细胞株
公司分类: CRISPR_Cell_lines
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Technical Details

Source
Expressed in E. coli
Description

Human IL-6, accession # P05231, Pro29-Met212

Formulation

Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5

Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.

 PreclinicalGMP
Molecular weight21.9 kDa21.9 kDa
Purity≥ 95% as determined by SDS-PAGE≥ 97% as determined by SDS-PAGE
Activity≥ 80 x 106 IU/mg, calibrated against NIBSC #89/548 Measured in a cell proliferation assay using an IL-6-dependent cell line, B980 – 250 x 106 IU/mg, calibrated against NIBSC #89/548 Measured in a cell proliferation assay using an IL-6-dependent cell line, B9

Batch specific activity on CoA

Endotoxin level< 1000 EU/mg≤ 50 EU/mg
Intended useIntended for preclinical ex vivo use. Not intended for therapeutic use.Intended for clinical ex vivo use. Not intended for human in vivo application.

Handling Instructions

Reconstitution

Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials and for 1 mg vials. We recommend to not vortex the solution. The solution can be turbid, this however does not influence the activity. 

Shipment

Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.

Expiry

≥ 6 months from date of shipping. Please refer to Certificate of Analysis for the exact expiry date.

Storage & Stability

Store lyophilized cytokine at -20°C to -80°C.

Store a 100 µg/ml reconstituted cytokine solution:

• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container. 

• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.

Avoid repeated freeze/thaw cycles.

Documents

  • Data Sheet: GMP or Preclinical
  • Material Safety Data Sheet: MSDS
  • Certificate of Analysis
  • Technote: ADCF and Serum-free Policy
  • Technote: Batch-to-Batch Consistency of CellGenix® GMP Cytokines
  • Technote: Stability of CellGenix® GMP Cytokines after Reconstitution
  • Technote: Shipment of CellGenix® Preclinical and GMP Cytokines at Ambient Temperatures
  • Technote: CellGenix® rh Cytokines - Preclinical vs GMP
  • More information under Resources

Data

CellGenix GMP rh IL-6 has an activity of 80 – 250 × 106 IU/mg

The activity of GMP rh IL-6 was measured in a cell proliferation assay using the IL-6-dependent cell line B9. It was calibrated against the NIBSC #89/548.

You can find the batch specific activity on the certificate of analysis (CoA).

IL6, Interleukin6

Publications

  • 3′, 4′-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.Kaur, K. et al., 2013, Stem Cell Research & Therapy
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeDanull, J. et al., 2013, The Journal of Clinical Investigation
  • Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyHansen, M. et al., 2013, Vaccine
  • Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsRidolfi, L. et al., 2013, Journal of Translational Medicine
  • Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaVik-Mo, EO. et al., 2013, Cancer Immunology Immunotherapy
  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesPellegatta, S. et al., 2013, Oncoimmunology
  • Validation of analytical methods in compliance with good manufacturing practice: a practical approachRustichelli, D. et al., 2013, Journal of Translational Medicine
  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastomaNava, S. et al., 2012, PloS One
  • A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaChia, WK. et al., 2012, Annals of Oncology
  • Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture ProcessSpanholtz, J. et al., 2011, PloS One
  • Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcomeRidolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patientsLesterhuis, WJ. et al., 2010, Anticancer Research
品牌介绍
CellGenix在细胞,基因治疗和再生医学领域的GMP制造和产品开发(用于树突细胞,HSC,脐带血细胞和软骨细胞)方面拥有超过二十五年的内部专业知识。该公司成立于1994年,是弗莱堡大学医学中心的一部分,是1995年第一家获得GMP制造授权用于细胞处理的欧洲公司。CellGenix当前的质量管理(QM)系统是根据德国监管机构的生产许可建立的,用于生产符合GMP的重组蛋白研究产品(患者特定型疫苗和重组肿瘤疫苗)。QM系统适用于重组原料的生产,并自2012年起获得ISO认证(目前为DIN EN ISO 9001:2015)。 在细胞和基因治疗领域活跃了许多年,CellGenix一直对在这种不断发展的环境中支持调节框架的发展抱有浓厚的兴趣。我们于2002年提交了第一个针对细胞因子作为辅助试剂的FDA DMF,并于2010年与USP共同撰写了第<92>章。为了满足ATMP制造对GMP优质原材料日益增长的需求,我们现在正在投资扩大产能,并正在建设更多的研发实验室,生产和仓库空间。升级还为现有GMP设施中的重组蛋白产品引入了最新的自动化大规模生产能力。